Ignite Creation Date:
2024-05-06 @ 1:56 PM
Last Modification Date:
2024-10-26 @ 1:22 PM
Study NCT ID:
NCT04161495
Status:
COMPLETED
Last Update Posted:
2023-05-24
First Post:
2019-11-05
Brief Title:
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein Efanesoctocog Alfa BIVV001 in Patients With Severe Hemophilia A
Sponsor:
Bioverativ a Sanofi company
Organization:
Sanofi
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-11-19
Start Date Type:
ACTUAL
Primary Completion Date:
2022-02-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-02-03
Completion Date Type:
ACTUAL
First Submit Date:
2019-11-05
First Submit QC Date:
November 11 2019
Study First Post Date:
2019-11-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2023-05-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-04-28
Last Update Post Date:
2023-05-24
Last Update Post Date Type:
ACTUAL